United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

It's important to look beyond the headlines and find out more about how effective coronavirus vaccine candidates are.

What Data This Coronavirus Expert Is Looking For In Pfizer and Moderna's Vaccine Trials

AstraZeneca

BioNTech SE

Johnson & Johnson

Novavax

Should You Buy a Basket of Late-Stage Coronavirus Vaccine Stocks?

GoodRx Holdings

Nintendo

GoodRx, Nintendo, and Roku are all great growth investments to hang on to for the long term.

The Pandemic's Still Not Over: 3 Stay-at-Home Stocks to Buy Right Now

It could help Americans feel more confident about getting vaccinated for COVID-19.

The Biggest Takeaway From Pfizer's Coronavirus Vaccine Results

Takeda Pharmaceutical

The numbers are close, but two players stand out at the moment.

Which Coronavirus Vaccine Maker Is Poised to Be the Top Supplier?

Shares of Pfizer Inc. (NYSE: PFE) have received a price target increase from $43 to $44 by Mizuho Securities. These are the details.

Pfizer (PFE) Stock Price: $44 Target By Mizuho Securities

If approved and launched, an mRNA vaccine would disrupt the vaccine development landscape and go leaps and bounds toward helping the world recover from the pandemic.

Here's Why Pfizer's Coronavirus Vaccine Would Be Revolutionary

The best way to pick coronavirus stocks is to make sure you trust the scientists running the company's COVID-19 program.

How To Invest In COVID-19 Vaccine Stocks: Bet On The Jockey

ConocoPhillips

Chevron

These oil stocks look like they have lots of room to run.

Vaccine Hopes Sent These 3 Oil Stocks Up More Than 15%: Here's Why They're Still Cheap

Getting FDA authorization for a COVID-19 vaccine may be just the first hurdle of many.

Coronavirus Vaccine Stocks: Challenges With Manufacturing, Distribution, And the Cold Chain

How seismic was the stock-market move that kicked off the week following news of an effective coronavirus vaccine candidate? It was the best week ever for inflows, according to BofA Global Research

The Tell: Pfizer vaccine news sparks $44.5 billion flood into the stock market—its biggest weekly inflow ever, says BofA

Any first-mover advantage won't last long, as some vaccine candidates may be easier to transport and administer than others.

Pfizer Has A Head Start, But The Covid-19 Vaccine Market Is Still Up For Grabs

The biggest catalyst for global equities: COVID-19 vaccine.

Global stock funds see record inflows on Pfizer's COVID-19 vaccine

Pfizer stock jumped in early November after the pharma company's coronavirus vaccine proved 90% effective in a final-phase study. But if the pharmaceutical company's stock a buy now?

Is Pfizer Stock A Buy After Its Coronavirus Vaccine Proved 90% Effective?

BioNTech and Pfizer Inc.'s unexpectedly efficacious COVID-19 vaccine candidate caught Wall Street and the medical community by surprise this week, yet the same experts who are thrilled by the news caution that the effectiveness of the vaccine will likely be lower in the real world.

BioNTech and Pfizer's COVID-19 vaccine is surprisingly effective, though experts question what effectiveness will look like in the real world

Amid some volatility, the S&P 500 has climbed nearly 2.5% in the past week. The triggers?

Pfizer's Covid-19 Vaccine News Is Pushing These 18 Stocks Up – Time To Invest?

Here are pharmaceutical stocks for November 2020 with a focus on companies that are close to delivering a vaccine against Covid-19. The post 3 Pharmaceutical Stocks to Buy in November appeared first on InvestorPlace.

3 Pharmaceutical Stocks to Buy in November

Pfizer said sale of shares by Albert Bourla was prearranged under plan set up in August

Pfizer's CEO sold $5.6 million worth of shares on the day of its big vaccine news. So what?

Hain Celestial Group

Pilgrim's Pride

Tyson Foods

United Natural Foods

The Hain Celestial Group, Inc. (HAIN), United Natural Foods, Inc. (UNFI) and Tyson Foods, Inc. (TSN) may one again witness a surge in the demand for their products as surging coronavirus cases may once again compel people to confine themselves indoors.

Coronavirus Fears to Boost Packaged Food Sales: 4 Picks

Bank of America

Citigroup

Citizens Financial Group

Fifth Third Bancorp

First Republic

Huntington Bancshares

JPMorgan Chase & Co

KeyCorp

SPDR S&P Regional Banking ETF

M&T Bank

PNC Financial Services

Regions Financial

Truist Financial

All banks are anticipating loan losses due to the pandemic, but the regional players appear more exposed to those risks than both their larger and smaller peers.

Why Regional Bank Stocks Will Benefit More From a COVID-19 Vaccine

Carnival

SunPower

After the volatility of 2020, analysts see some calm in the offing. Here are 5 companies to invest in on those prospects.

5 Companies to Invest in for 2021 as Markets Price in Economy's Prospects

Pfizer Inc (NYSE: PFE) is in negotiations with the government of Brazil to supply its COVID-19 vaccine to the country, Reuters reported Thursday. What Happened: The negotiations are reportedly centered around supplying the vaccine in the first quarter of 2021.

Pfizer Negotiates COVID-19 Vaccine Supply With Brazil For Early Next Year

Pfizer CEO Albert Bourla sold shares worth more than triple his base salary on Monday, hours after proclaiming that excellent results from the pharmaceutical company's COVID-19 vaccine in a late-stage trial made it a "great day for science and humanity." Bourla described the results in a press release as a "critical milestone" in the race to develop a vaccine, and a "significant step" towards ending the coronavirus pandemic. Pfizer's stock price jumped as much as 15% on the news.

Pfizer's CEO cashed out $5.6 million of stock after trumpeting its COVID-19 vaccine. That's 30% of his total compensation last year

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the publication of an analysis showing that VYNDAQEL® (tafamidis meglumine) 80 mg/VYNDAMAX® (tafamidis) 61 mg were associated with a statistically significant improvement in long-term survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared to VYNDAQEL 20 mg, reaffirming optimal dosing for these patients. Results from the analysis of the Phase 3 Tafamidis in Transthyretin Amyloid Cardiomyopathy Clinical

Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg

Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.

News for Pfizer Stock (PFE)